Survival prognosis in advanced HER-2 negative gastric cancer treated with immunochemotherapy: A novel model

Table 1 Baseline characteristics, n (%)

Characteristics	Total (n = 200)	Text (n = 60)	Train (n = 140)	Statistic	P value
Sex				χ2 = 0.63	0.426
Male	75 (37.50)	25 (41.67)	50 (35.71)
Female	125 (62.50)	35 (58.33)	90 (64.29)
Age				χ2 =0.02	0.899
< 60	78 (39.00)	23 (38.33)	55 (39.29)
≥ 60	122 (61.00)	37 (61.67)	85 (60.71)
BMI, kg/m2				χ2 =0.11	0.742
< 25	166 (83.00)	49 (81.67)	117 (83.57)
≥ 25	34 (17.00)	11 (18.33)	23 (16.43)
CEA, ng/mL				χ2 =0.01	0.925
< 3	121 (60.50)	36 (60.00)	85 (60.71)
≥ 3	79 (39.50)	24 (40.00)	55 (39.29)
CA199, U/mL				χ2 =0.60	0.440
< 37	128 (64.00)	36 (60.00)	92 (65.71)
≥ 37	72 (36.00)	24 (40.00)	48 (34.29)
ECOG PS				χ2 =0.20	0.653
0	72 (36.00)	23 (39.33)	49 (35.00)
1	128 (64.00)	37 (61.67)	91 (65.00)
Staging				χ2 =0.28	0.598
3	89 (44.50)	25 (41.67)	64 (45.71)
4	111 (55.50)	35 (58.33)	76 (54.29)
Site				χ2 =0.23	0.634
Stomach	142 (71.00)	98 (70.00)	44 (73.33)
Gastric and esophageal binding	58 (29.00)	72 (30.00)	16 (26.67)
Differentiation				χ2 =1.06	0.304
Low	180 (90.00)	56 (93.33)	124 (88.57)
Medium-high differentiation	20 (10.00)	4 (6.67)	16 (11.43)
Peritoneal metastasis				χ2 =0.81	0.367
No	113 (56.50)	31 (51.67)	82 (58.57)
Yes	87 (43.50)	29 (48.33)	58 (41.43)
Liver metastasis				χ2 =2.15	0.143
No	157 (78.50)	51 (85.00)	106 (75.71)
Yes	43 (21.50)	9 (15.00)	34 (24.29)
EBV status				χ2 =0.06	0.802
No-infect	187 (93.50)	57 (95.00)	130 (92.86)
Infect	13 (6.50)	3 (5.00)	10 (7.14)
PD-L1 expression				χ2 =0.65	0.419
CPS < 5	88 (44.00)	29 (48.33)	59 (42.14)
CPS ≥ 5	112 (56.00)	31 (51.67)	81 (57.86)
MMR status				χ2 =0.31	0.579
pMMR	169 (84.50)	52 (86.67)	117 (83.57)
dMMR	31 (15.50)	8 (13.33)	23 (16.43)
CALLY index, median (Q1, Q3)	1.13 (0.18, 4.99)	1.25 (0.17, 3.15)	1.03 (0.18, 5.19)	Z = -0.42	0.674
NLR, median (Q1, Q3)	2.58 (1.81, 4.17)	2.61 (1.88, 4.04)	2.57 (1.72, 4.30)	Z = -0.30	0.762
SII, median (Q1, Q3)	627.11 (339.65, 939.08)	661.80 (361.13, 883.91)	613.29 (325.57, 998.95)	Z = -0.53	0.598

BMI: Body mass index; CEA: Carcinoembryonic antigen; CA199: Carbohydrate antigen 199; ECOG PS: Eastern Cooperative Oncology Group performance status; EBV: Epstein-Barr virus; PD-L1: Programmed cell death ligand 1; CPS: Combined positive score; MMR: Mismatch repair; pMMR: Proficient mismatch repair; dMMR: Deficient mismatch repair; NLR: Neutrophil-to-lymphocyte ratio; CALLY: C-reactive protein-albumin-lymphocyte; SII: Systemic immune inflammation.